Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: A national cross-sectional study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1720-1722

  Hwang, Thomas J ^a,b   Hooper, David C ^c  

^a HARVARD UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ambulatory care; Antimicrobial resistance; E. coli; Evidence based prescribing; Public health; Surveillance; Urinary tract infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL MUTATION; BACTERIUM ISOLATE; DISEASE SURVEILLANCE; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; GRAM NEGATIVE BACTERIUM; HUMAN; LETTER; NONHUMAN; PRESCRIPTION; URINARY TRACT INFECTION; AMBULATORY CARE; CROSS-SECTIONAL STUDY; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; OUTPATIENT; URINARY TRACT INFECTIONS;

AMBULATORY CARE; ANTI-INFECTIVE AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; OUTPATIENTS; URINARY TRACT INFECTIONS;

EID: 84903896145     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku029     Document Type: Letter

References (10)

1. Adriaenssens N, Coenen S, Versporten A et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011; 66 Suppl 6: vi47-56.
2. Kallen AJ, Welch HG, Sirovich BE. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 2006; 166: 635-9.
3. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
4. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-40.
5. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9.
6. Robicsek A, Strahilevitz J, Sahm DF et al. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006; 50: 2872-4.
7. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 1999; 29: 259-63.
8. Strahilevitz J, Jacoby GA, Hooper DC et al. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664-89.
9. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-6.
10. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-8.